Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$72.51MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Melissa Tomkiel
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 327
- Beta
- 2.26
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 4.74
Financials
Revenue
$72.51M+1288.2%Net Income
$-10.52M-10707.3%EBITDA
$-2.00MFree Cash Flow
$3.50M+138.7%EPS (diluted)
$-0.12-889.5%Shares Outstanding (diluted)
86.21M+1221.6%Operating Expenses
$9.19MCash & Debt
$22.75MReturn of Capital
$0.00Revenue by Segment (annual)
$197.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $197.14M | $41.35M | $0.50 |
| 2024 | $248.69M | $-27.31M | $-0.35 |
| 2023 | $225.18M | $-56.08M | $-0.76 |
| 2022 | $146.12M | $-27.26M | $-0.38 |
| 2021 | $50.53M | $-40.05M | $-0.57 |
| 2020 | $23.43M | $-10.16M | $-0.81 |
| 2019 | $31.20M | $-10.84M | $-1.47 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.74
- Implied price
- $7.37
- Return from $4.81
- 8.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.66 — -23.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -2.0% | -10.8% | -5.5% | -1.2% | 2.5% | 5.7% |
| 3.0% | -6.2% | -0.7% | 3.9% | 7.7% | 11.1% |
| 8.0% | -1.7% | 4.1% | 8.9% | 12.9% | 16.5% |
| 13.0% | 2.9% | 9.0% | 13.9% | 18.2% | 21.9% |
| 18.0% | 7.4% | 13.8% | 19.0% | 23.4% | 27.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
40-77.25%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·30d ago·Negative
…al to Present at the 2026 Jefferies Healthcare Services and Technology Conference NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026, at 2:15 pm ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the…
View source ↗ - Newszacks.com·45d ago·Positive
Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock? Strata Critical Medical, Inc. (SRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·45d ago·Positive
Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect? The mean of analysts' price targets for Strata Critical Medical, Inc. (SRTA) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗
Earnings
Mon, Nov 9(in 4 weeks)
Consensus estimate $0.01 per share
Typical surprise -25.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.12 vs $-0.02miss
- Wed, May 6$0.03 vs $-0.04beat
- Tue, Mar 3$-0.06 vs $0.01miss
- Mon, Nov 10$-0.06 vs $-0.02miss
- Tue, Aug 5$-0.05 vs $-0.04miss
- Mon, May 12$-0.04 vs $-0.11beat
Estimates and results for SRTA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SRTA officers and directors.
- Bought
- $98k
- Sold
- $927k
2 trades
10 trades
- Love Reginaldsold
- Heyburn William A.sold
- Cohen Amirsold
- Tomkiel Melissa M.sold
- Wunsch Scott Msold
- Cohen Amirsold
- Cohen Amirsold
- Cohen Amirsold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SRTA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.